The editorial introduces eight studies on plants and fungi used in functional-food and nutraceutical development. Contributions span chemical characterisation, mechanisms, biological models and clinical assessment.

Its industrial value is not tied to one molecule but to the methodological sequence: define the material, understand its constituents, observe a mechanism and test whether the result transfers to a product and population.

For R&D and procurement, botanical origin and naturalness do not replace specifications, markers, extraction process, stability and variability control. For scientific marketing, rationale must remain distinct from finished-product evidence.

The editorial does not provide a new efficacy demonstration and brings together heterogeneous studies. It is best read as a map of research directions, not permission to generalise one extract or model to a category.

Why it matters

For ingredient discovery, continuity among material identity, mechanism, dose, process and actual use context is the central issue.

Evidence limit

This is an editorial synthesis, not a new trial. The eight studies cover different materials, models and evidence levels and do not support one efficacy conclusion.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · Frontiers in Pharmacology ↗